《大行報告》野村下調百濟神州(06160.HK)目標價至170.15元 評級「買入」
野村發表發表報告,指百濟神州(06160.HK)第三季銷售按年增88%,按季增8%至3.88億美元,強勁的增長受惠於BTK抑製劑Zanubrutinib和PD-1抑制劑tislelizumab,分別於第三季貢獻1.55億美元及1.28億美元銷售額,按年增136%和67%。
該行表示,上述銷量增長相當令人鼓舞,因為人民幣兌美元走弱,意味表明PD-1抑制劑tislelizumab在內地銷售增長按季接近30%,並認為BTK抑製劑Zanubrutinib在美國的銷售增長也令人滿意。該行預料,BTK抑製劑Zanubrutinib的強勁上升走勢可保持至今年第四季,分別呈按年增94%及按季增9%;至於PD-1抑制劑tislelizumab則料持平。
該行表示,將公司今年及明年收入預測上調5%及1%,同時將今年及明年淨虧損上調11%及8%,以反映匯兌損失,並將其H股目標價由172.89元下調至170.15元,維持其評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.